Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
Rhea-AI Summary
Alcon (NYSE:ALC) and RxSight (NASDAQ:RXST) entered a non-exclusive license and development agreement to create adjustable presbyopia-correcting intraocular lenses (PCIOLs).
RxSight receives a $60 million upfront payment, up to $140 million in development and regulatory milestones, and royalties, while Alcon leads global commercialization and RxSight handles development and manufacturing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Upfront payment of $60 million to RxSight to begin development
- Potential additional milestone payments of up to $140 million to RxSight
- RxSight to receive royalties on net sales of co-developed PCIOLs
- Alcon to lead global commercialization, leveraging its established eye care footprint
- Collaboration combines RxSight light-adjustable tech with Alcon PCIOL optics
Negative
- Agreement is non-exclusive, allowing Alcon to work with other adjustable PCIOL partners
- Milestone payments up to $140 million depend on development and regulatory achievements
- RxSight responsible for development and manufacturing, implying ongoing execution and cost obligations
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | conference participation | Neutral | +1.2% | Announcement of participation in the Stifel 2026 Virtual Ophthalmology Forum. |
| May 06 | earnings report | Negative | -14.4% | Q1 2026 results with revenue decline, net loss, and reiterated full-year outlook. |
| Apr 29 | conference participation | Neutral | +3.8% | Planned presentation at the Bank of America Healthcare Conference with webcast access. |
| Apr 22 | earnings date notice | Neutral | -2.7% | Scheduling announcement for Q1 2026 financial results release and conference call. |
| Apr 08 | product milestone | Positive | -7.0% | Milestone of 300,000 Light Adjustable Lens implants and strong ASCRS 2026 presence. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historically, RxSight’s shares have sometimes sold off on positive corporate news, showing a mix of aligned and divergent reactions.
Regulatory & Risk Context
Short interest was at a moderate level, indicating some potential for volatility or squeezes but not extreme bearish positioning.
Key Terms
presbyopia-correcting intraocular lenses medical
post-operative light-adjustable technology medical
intraocular lens medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies
- Collaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery
ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).
Under the collaboration, the companies will be innovating on their respective platforms – RxSight's post-operative light-adjustable technology and Alcon's PCIOL optical designs – and combining them to create a co-developed technology that enables surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL.
“Our leading PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery,” said David J. Endicott, Chief Executive Officer of Alcon. “Together with RxSight’s technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery.”
“We are excited to work with Alcon to provide patients greater access to outcomes customized to their needs after surgery,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “This collaboration underscores our belief in the importance of adjustability and will help accelerate its expansion across a wider base of patients.”
As part of the agreement, RxSight will receive a
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements in this press release that are not purely historical are forward-looking statements, including, without limitation, statements regarding: potential payments that may be received by us in connection with the collaboration, including potential milestone payments and royalties; and RxSight’s and Alcon’s respective rights and obligations under the collaboration agreement, a description of which (including material terms and conditions) may be found in the Current Report on Form 8-K filed of even date herewith with the Securities and Exchange Commission (SEC). The forward-looking statements contained herein are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including, without limitation, uncertainty as to whether the anticipated benefits and opportunities of the proposed collaboration may be realized or make take longer to realize or may cost more than expected; risks of unexpected hurdles, costs or delays; challenges in technology transfer and manufacturing; challenges inherent in new product candidate development, including obtaining regulatory approvals; challenges associated with collaborating with third parties, including intellectual property, operational, financial and other risks; uncertainty of commercial success for new products; the ability of RxSight and Alcon to successfully execute their respective strategic plans; and other risks that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Securities and Exchange Commission (SEC) on May 6, 2026, and other documents that RxSight files from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and RxSight assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Connect with us on
https://www.facebook.com/rxsight/
https://www.linkedin.com/company/rxsight/
https://www.instagram.com/rxsight/
http://www.youtube.com/@rxsight
| Investor Relations | Media Relations |
| Oliver Moravcevic | Robert Spirito |
| omoravcevic@rxsight.com | rspirito@rxsight.com |
